ARS Pharmaceuticals, Inc. (SPRY) announced on Wednesday that it has submitted its response to the Complete Response Letter or CRL from FDA for its New Drug Application for Neffy also known as epinephrine nasal spray, to treat Type I allergic reactions, including anaphylaxis.
The company's response addresses all additional requests made by the FDA following the CRL in September 2023.
This includes positive data from a repeat dose PK/PD study of Neffy under nasal allergen challenge conditions, as well as updated testing that found no detectable nitrosamine levels.
The company expects the FDA review to last up to six months, with the PDUFA date set for October 2, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.